ASH 2025 | Updated data on bexobrutideg in Waldenström’s macroglobulinemia: an ongoing Phase Ia/b trial

So bexobrutideg is one of a couple of BTK degraders that’s being developed right now for B-cell malignancies. And this data was presented now at a couple of conferences, and we have updated data here at ASH 2025. There’s actually going to be a CLL oral presentation that I’m a part of. And then there’s data in Waldenstrom’s macroglobulinemia that I am the lead author and will be presenting a poster on during this meeting. Focusing on that Waldenstrom’s data, this was a smaller cohort of patients with Waldenstrom just being a less common disease. But in their cohort of about 25-ish patients, all of whom were prior covalent BTKi exposed, bexobrutideg was given as a therapeutic option, thinking about resistance. So BTK degraders can potentially overcome resistance mechanisms to covalent BTK inhibitors by their mechanism of action of degrading the entire BTK molecule. And so that’s why we’re really excited by this class in Waldenstrom’s and CLL and other B-cell malignancies. In the data for Waldenstrom’s, we show that despite, you know, having exposure to a covalent BTK inhibitor, 85% overall response rate. And so that’s really quite incredible when you think about this. These responses were durable, although the follow-up is still limited. But we saw IgM reductions in about 80% of patients. And then in terms of toxicity, this class of drugs seems to be generally well tolerated. There were only two sort of treatment-related discontinuations, and the majority of AEs were grade one to two and manageable for patients. So early data in Waldenstrom’s, but for a disease with few therapeutic options, I think it’s nice to see that a new class of drugs has potential promise. And, you know, we hope to continue to work with the BTK degrader class in Waldenstrom’s, in CLL, and potentially other B-cell malignancies as well.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.